According to the latest semi-annual report of Fosun Pharma, its operating income reached 6.9 billion yuan, a year-on-year increase of 17.15% and a net profit of 1.5 billion yuan. Mergers and acquisitions have brought considerable income to Fosun Pharma, but since Fosun Pharma itself does not have a medical enterprise production business, it is still unknown whether there will be sustainable high performance after mergers and acquisitions. Mergers and acquisitions have become the new darling of domestic pharmaceutical companies, but their subsequent integration will face even greater challenges.
Medical device agent high growth rate
The 2016 semi-annual report released by Fosun Pharma recently showed that the company achieved operating income of 6.9 billion yuan in the first half of 2016, a year-on-year increase of 17.15% and a net profit of 1.5 billion yuan, a year-on-year increase of 15.1%. It is worth noting that in the four business segments of Fosun Pharma, pharmaceutical manufacturing and R&D revenues were 4.85 billion yuan, up 17.67% year-on-year; medical service revenue was 750 million yuan, up 11.67% year-on-year; medical diagnosis and medical treatment Equipment manufacturing revenue was 950 million yuan, up 14.15% year-on-year; medical diagnostics and medical device agents became the fastest growing segment, with revenue of 370 million yuan, an increase of 31.41%.
The financial report shows that the increase in the company's agency business income is mainly due to the increase in the number of Da Vinci surgical robots and the increase in the amount of surgery, which has led to an increase in sales of consumables. It is understood that the Da Vinci surgical robot is the only surgical robot that has been approved by the US FDA and the China Food and Drug Administration.
The relevant person in charge of Fosun Pharma has said that the future income of robots is mainly derived from the sales and consumables of Da Vinci surgical robots.
(Fosun medicine is taking risks: breaking into the field of medical devices)
M&A that can't stop
In addition to the sales of surgical robots and consumables, AlmaLasers has become another highlight in Fosun Pharma's financial report in the medical diagnostics and medical device agency sector.
AlmaLasers is an Israeli-based medical beauty equipment manufacturer that was acquired by Fosun Pharma in 2013. AlmaLasers achieved operating income of 380 million yuan in the first half of 2016, an increase of 15.99% over the same period in 2015.
It is worth noting that the sales of Da Vinci surgical robots and AlmaLasers, which brought the profit growth highlights to Fosun Pharma in this financial report, were obtained through mergers and acquisitions. The industry believes that the benefits of medical device agents acquired by Fosun Pharma are prominent, which makes Fosun Pharma taste the sweetness, and the outsourcing of Fosun Pharma will continue.
According to the development strategy of Fosun Pharma in the second half of the year, AlmaLasers will speed up the development and sales of medical therapeutic devices, and at the same time carry out the construction of laser beauty center and medical beauty clinic to realize the extension from equipment supply to service. Chen Qiyu, chairman of Fosun Pharma, said that in the second half of the year, Fosun Pharma will adhere to the development strategy of “endogenous growth, extensional expansion, and integrated development†and increase the acquisition and integration of outstanding pharmaceutical companies at home and abroad.
Shi Lichen, head of Beijing Dingchen Medical Consulting Center, said that although the medical device agent has become the biggest highlight of Fosun Pharma, but Fosun Pharma itself does not have a medical enterprise production business, the current business is obtained through mergers and acquisitions, so in terms of medical devices. In the future, the company will not shift its focus to this area and will not show too much performance. The industry believes that pharmaceutical and research and development, revival medicine is a veteran, breaking into medical diagnosis and medical equipment, in the end how to wait for market test and time test.
We're professional Otology Instruments manufacturers and suppliers in China, specialized in providing high quality medical instruments with reasonable price. We warmly welcome you to buy or wholesale bulk Otology Instruments for sale here and get quotation from our factory.
Ent Forceps,Ent Ear Instruments,Otology Instruments,Forceps Ent Instruments
Tonglu WANHE Medical Instrument Co., Ltd , https://www.tlvanhurhealth.com